Akorn, Natco Pharma Add Products To API Supply Pact

Akorn, Inc. has added two injectable drug products to its API Supply and Margin Sharing Agreement with Natco Pharma Ltd. One of the ANDA drug products is for the prevention of nausea and vomiting associated with cancer chemotherapy, and the other product is for the reduction of renal toxicity and xerostomia in cancer patients undergoing chemotherapy and radiation. According to 2006 IMS data, the market size for the two finished products is approximately $433 million.

Under the agreement, Natco will be responsible for the supply of the API for both drug products. Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the U.S. and Canada.

Arthur S. Przybyl, Akorn’s president and chief executive officer stated, “We are excited to expand our business partnership with Natco Pharma. These two products will continue to build upon our anti-cancer drug product franchise.”

Rejeev Nannapaneni, Natco Pharma’s chief operating officer stated, “We are happy to continue this fruitful partnership with Akorn.”